Nitric oxide-releasing prodrug molecule of substituted quinazolines
US10456405B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Sep 6, 2016 |
| Grant date | Oct 29, 2019 |
| Priority date | — |
| Expiry date | Sep 6, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D239/91
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are a compound of the formula below, and a pharmaceutically acceptable salt or stereoisomer thereof that can be used for treating cardiovascular diseases and compositions containing the compounds. The compounds, a pharmaceutically acceptable salt or stereoisomer thereof and the compositions can improve lipid metabolism disorders by increasing high-density lipoprotein cholesterol in blood; in addition, the compounds, a pharmaceutically acceptable salt or stereoisomer thereof and the compositions can also release nitric oxide, and reduce the onset risk of cardiovascular diseases by means of relaxing blood vessels, lowering blood pressure, inhibiting platelet adhesion and aggregation and maintaining vascular tension, and thus play an important role in preventing and treating the occurrence and development of cardiovascular diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.